Launch Sequence Aphrodisia Capsules — Class II drug recall D-1341-2022
Terminated recall by Loud Muscle Science, reported 2022-07-27, distributed nationwide. Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.
| Recall number | D-1341-2022 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Loud Muscle Science, Hauppauge, NY, United States |
| Recall initiated | 2022-06-27 |
| Classified | 2022-08-15 |
| Reported by FDA | 2022-07-27 |
| Terminated | 2023-02-08 |
| Distributed | Nationwide (US) |
| Countries outside the US | CA |
| Reason classes | labeling, unapproved product |
| UPC / GTIN / UDI-DI | 00661020846957 |
| Lot numbers | C07172101 |
| Expiration dates | 2024-07 |
Product
Launch Sequence Aphrodisia Capsules, 4-count tins, ASIN B07QB3S2LV, UPC Code 661020846957.
Reason for recall
Marketed Without An Approved NDA/ANDA: Unapproved Drug based on label claims.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1341-2022. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.